title: The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model.
abstract: Selegiline is a selective irreversible inhibitor of the B-type of monoamine oxidase (MAO-B). The spectrum of its pharmacological activity is wide, possesses antioxidant, antiapoptotic and neuroprotective properties and, additionally, we found it is effective on the total scavenger capacity (TSC), and the regulation of fat content in rat liver kept on lipid-rich diet. Our aim was to clarify whether the oral treatment with selegiline is protective on oxidative damage of Sprague-Dawley adult rats in vivo. Four groups of rats (five animals in a group) were examined: (1) lipid-rich diet, (2) normal rat food, (3) lipid-rich diet + selegiline and (4) normal rat food + selegiline. Selegiline solution (2.5 µg/ml) was supplied with the drinking water, which was freely available for the animals. Regarding the drinking habit of the rats (20-30 ml/day), the daily dose was roughly equal with that used in the human therapy (5-10 mg/day). TSC was determined both at the beginning (0 day) and at the end of the study (28 days), when the blood samples were taken for chemiluminometric assay. Fat content of the liver was determined in the freshly frozen tissue by Sudan staining. TSC was increased in both the selegiline-treated groups. Selegiline treatment prevented the increase of liver fat in the group fed with lipid-rich diet. Our results led us to the conclusion that prolonged selegiline administration can raise the antioxidant capacity of the animals and prevents the accumulation of fat in their livers.
authors.affiliation: Second Department of Medicine, Faculty of Medicine, Semmelweis University, 46 Szentkiralyi utca, Budapest 1088, Hungary. bekesi@bel2.sote.hu
authors.forename: Gabor
authors.initials: G
authors.lastname: Bekesi
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Tulassay
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lengyel
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Schaff
authors.forename: Dezso
authors.initials: D
authors.lastname: Szombath
authors.forename: Julia
authors.initials: J
authors.lastname: Stark
authors.forename: Istvan
authors.initials: I
authors.lastname: Marczell
authors.forename: Peter
authors.initials: P
authors.lastname: Nagy-Repas
authors.forename: Ildiko
authors.initials: I
authors.lastname: Adler
authors.forename: Elek
authors.initials: E
authors.lastname: Dinya
authors.forename: Karoly
authors.initials: K
authors.lastname: Racz
authors.forename: Kalman
authors.initials: K
authors.lastname: Magyar
mesh_terms: D050154:Adiposity / Q000187:drug effects; D000818:Animals; D004195:Disease Models, Animal; D005234:Fatty Liver / Q000517:prevention & control*; D016166:Free Radical Scavengers / Q000378:metabolism*; D008163:Luminescent Measurements / Q000379:methods; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012642:Selegiline / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D016166:Free Radical Scavengers; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline